PFKL Antibody (YT4): sc-100542
- PFKL Antibody (YT4) is a mouse monoclonal IgG2a κ provided at 100 µg/ml
- raised against recombinant PFKL of human origin
- recommended for detection of liver type PFKL of mouse, rat and human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for PFKL Antibody (YT4). This work is in progress.
QUICK LINKS
SEE ALSO...
PFKL Antibody (YT4) is a mouse monoclonal IgG2a antibody that detects phosphofructokinase, liver (PFKL) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). PFKL is a crucial regulatory enzyme in the glycolytic pathway, catalyzing the irreversible conversion of fructose-6-phosphate to fructose-1,6-bisphosphate, a key step in glucose metabolism. This enzyme is predominantly expressed in tissues involved in gluconeogenesis, such as the liver and kidney, where PFKL plays a significant role in regulating energy production and glucose homeostasis. The structure of PFKL as a tetramer, composed of various isoenzymes, allows for complex regulation and adaptation to metabolic demands, making PFKL essential for maintaining proper cellular function. Notably, alterations in PFKL expression have been linked to metabolic disorders, including PFKL overexpression in Down′s syndrome patients, which may contribute to the pathogenesis of the condition. Anti-PFKL antibody (YT4) is an invaluable tool for researchers investigating the role of this enzyme in metabolic regulation and its implications in various diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
PFKL Antibody (YT4) References:
- Selective activation of PFKL suppresses the phagocytic oxidative burst. | Amara, N., et al. 2021. Cell. 184: 4480-4494.e15. PMID: 34320407
- Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner. | Zheng, C., et al. 2022. Acta Pharm Sin B. 12: 1271-1287. PMID: 35530161
- A functional loop between YTH domain family protein YTHDF3 mediated m6A modification and phosphofructokinase PFKL in glycolysis of hepatocellular carcinoma. | Zhou, R., et al. 2022. J Exp Clin Cancer Res. 41: 334. PMID: 36471428
- The KLF7/PFKL/ACADL axis modulates cardiac metabolic remodelling during cardiac hypertrophy in male mice. | Wang, C., et al. 2023. Nat Commun. 14: 959. PMID: 36810848
- Caveolin-1 depletion attenuates hepatic fibrosis via promoting SQSTM1-mediated PFKL degradation in HSCs. | Zhang, Y., et al. 2023. Free Radic Biol Med. 204: 95-107. PMID: 37116593
- Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness. | Chen, S., et al. 2023. Cell Rep. 42: 113246. PMID: 37831605
- EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL. | Pan, M., et al. 2024. J Exp Clin Cancer Res. 43: 35. PMID: 38287371
- Ubiquitin-specific protease 14 targets PFKL-mediated glycolysis to promote the proliferation and migration of oral squamous cell carcinoma. | Zhang, X., et al. 2024. J Transl Med. 22: 193. PMID: 38388430
- Glycolytic enzyme PFKL governs lipolysis by promoting lipid droplet-mitochondria tethering to enhance β-oxidation and tumor cell proliferation. | Meng, Y., et al. 2024. Nat Metab. 6: 1092-1107. PMID: 38773347
- Phosphorylation of PFKL regulates metabolic reprogramming in macrophages following pattern recognition receptor activation. | Wang, M., et al. 2024. Nat Commun. 15: 6438. PMID: 39085210
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PFKL Antibody (YT4) | sc-100542 | 100 µg/ml | $339.00 |